Metsera, Inc. (NASDAQ:MTSR – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $29.16, but opened at $28.00. Metsera shares last traded at $28.04, with a volume of 95,958 shares traded.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price on the stock. Guggenheim began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target on the stock. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Finally, Evercore ISI began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating on the stock.
Read Our Latest Stock Analysis on MTSR
Metsera Stock Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
- Five stocks we like better than Metsera
- How to Plot Fibonacci Price Inflection Levels
- Energy Transfer: Powering Data With Dividends and Diversification
- How to Use the MarketBeat Stock Screener
- Qualcomm Stock Is Coiling for a Breakout
- Best Stocks Under $5.00
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.